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The lack of randomized, controlled trials (RCT) for inter-
ventional radiology (IR) is one of the major problems of
IR, which has been discussed for many years (SIR Dotter—
lecture 2008). The reasons for this are simple but difﬁcult
to overcome. IR does not control the patients, so they often
do not control the trials. Second, performing a RCT is
expensive and funding for device trials is very difﬁcult,
because there is still no regulatory need to produce RCT
data for registration of a device. Finally, the IR market is
small compared with, for example, interventional cardiol-
ogy, and the industry is not willing to invest large sums,
which are needed for a RCT. That is why we always see
these small, underpowered, one-arm studies in IR, never
reaching any level of evidence. The ASTRAL investigators
were able to overcome all of these hurdles and should
absolutely be congratulated for this. However, the question
remains how they were able to do this. I think personal
drive and commitment can be recognized, but there is
another method that they used, which is now the basis of
the ongoing discussion around the trial. Next to personal
commitment, the most often used method to recruit patients
is to ‘‘soften’’ the inclusion criteria, to make them more
acceptable, under the umbrella of otherwise being unethi-
cal. For this the authors introduced the so-called ‘‘uncer-
tainty principle’’ [1, 2]. They state that it is widely used and
even have a reference for this. It has never been used as far
as I know; I only know of the Heisenberg uncertainty
principle, which plays a role in quantum mechanics, to
state the precise inequalities of certain pairs of physical
properties, but this is probably something else. In their
reference, a Lancet publication from 1998, the word
uncertainly is mentioned three times in completely differ-
ent contexts, and the uncertainty principle is not anywhere
in this paper. The core of the discussion is that in the
ASTRAL trial patients could be included when the doctor
was uncertain whether the patient needed to be treated with
a stent. The problem is that there are currently no scientiﬁc
data for any doctor to be certain about this, which was just
the motivation for doing the ASTRAL trial. Therefore,
patient selection in the trial is based on the doctor’s gut
feeling, or any other personal reason. The authors further
state that this so-called uncertainty principle resulted in a
heterogeneous patient population. To my opinion, it only
resulted in serious patient selection bias. This uncertainty
could easily have been taken away if those patients who
received a stent, because the doctor was certain that they
needed one, were followed clinically to be certain that the
right decision was made. This was, however, not done,
which is a major ﬂaw. The authors state that many are
confused about the methodology and results of the
ASTRAL trial. I think there is no confusion at all; the
methodology and results are crystal clear. The conclusion
of the ASTRAL trial should be that if you, as a wise doctor,
think or feel that a patient needs to be treated with a stent,
you should do so, but if you are uncertain, which seems to
be rare looking at the ASTRAL inclusion data, the patient
should get best medical treatment. I am sure that the
ASTRAL investigators agree with this conclusion; how-
ever, nephrologists and other referring specialists read it
completely different because for them it says that there is
no advantage from renal stenting above best medical
treatment. That these words are coming directly from the
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DOI 10.1007/s00270-011-0114-1horse his mouth is not very helpful, as we can see in our
everyday practise.
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